Abstract
To the Editor The recent JAMA Insights article1 about the pathophysiology, diagnosis, and treatment of dry eye disease provided clear and concise information for practicing clinicians. However, other approaches for treatment of dry eye disease could have been mentioned, such as OC-01 (varenicline solution) nasal spray. In the primary phase 3 trial2 (ONSET-2) that included 758 patients with dry eye disease, treatment with OC-01 (varenicline solution) nasal spray for 4 weeks improved tear production and patient-reported symptoms compared with vehicle (control) nasal spray. In October 2021, this drug was approved by the US Food and Drug Administration for treatment of dry eye disease.